Table 4.
Case–control comparison with EUVAS trials
| CycLowVas cases | EUVAS controls | P-value | |
|---|---|---|---|
| n | 66 | 198 | |
| Baseline features | |||
| Female:male, n (%) | 28:38 (42:58) | 78:120 (40:60) | 0.66 |
| Age (years) median (range) | 63 (54.2–73) | 63 (53.25–71) | 0.75 |
| MPO:PR3 ANCA, n (%) | 33:33 (50:50) | 99:99 (50:50) | 1.00 |
| Baseline eGFR (mL/min), median (range) | 25.5 (18–43.7) | 27.1 (16.2–40.6) | 0.45 |
| Baseline BVAS, median (range) | 18.5 (15–21.75) | 18.5 (13–23.75) | 0.77 |
| Unadjusted outcomes at 6 months | |||
| Remission at 6 months, n (%) | 62/66 (96) | 141/151 (93.7) | 0.88 |
| 6-month eGFR (mL/min), median (range) | 49 (37.5–67) | 45.7 (31.8–62.23) | 0.14 |
| 6-month ΔeGFR (mL/min), median (range) | 13 (1.5–27.5) | 11.3 (1.5–24.15) | 0.30 |
| Cyclophosphamide dose (g), median (range) | 3 (3–3.5) | 13.5 (8.6–22.5) | <0.001 |
| Total corticosteroid dose (g), median (range) | 4.2 (1.0–6.5) | 5.3 (1.1–9.3) | <0.001 |
| Unadjusted long-term outcomes, n (%) | |||
| Relapse | 14/66 (21) | 61/198 (30.8) | 0.18 |
| Relapse PR3-ANCA | 5/33 (15) | 42/99 (42) | 0.008 |
| Relapse MPO-ANCA | 9/33 (27) | 19/99 (19) | 0.46 |
| ESRD | 4/66 (6) | 28/198 (14) | 0.12 |
| Death | 9/66 (13.6) | 46/198 (23.2) | 0.13 |
| Follow-up (days) median (range) | 1716 (964–2598) | 1878 (999–2946) | |